* If you want to update the article please login/register
Patients with acutely decompensated heart failure with a PAC are a multicenter, multirandomized, parallel group, adaptive trial that will determine whether early invasive hemodynamic evaluation and ongoing care with a PAC reduces hospital mortality in comparison to clinical care.
Source link: https://clinicaltrials.gov/ct2/show/NCT05485376
This registry is a non-interventional, multicentre retrospective cohort research in patients with acute myocardial infarction undergoing PCI after CRP, ventilated, and/or with cardiogenic shock. Patients with myocardial infarction are deemed eligible for participation in up to 20 high-volume PCI clinics in Germany treating patients with myocardial infarction. Patients with acute myocardial infarction who underwent PCI after CRP, ventilated,/or with cardiogenic shock, and/or with cardiogenic shock are treated with cangrelor during index therapy. Based on the patient's current medical records, patient characteristics, procedural information, and clinical events during the period between index MI and death would be documented.
Source link: https://clinicaltrials.gov/ct2/show/NCT04611607
The ANCHOR trial is also intended to see if VA-ECMO care combined with IABP results in improved outcomes in patients with AMI and cardiogenic shock with optimal medical care alone in patients with AMI and cardiogenic shock. Since new findings found survival up-to-50 percent with ECMO assistance in this setting, an ethical rescue option to VA-ECMO will continue to be used to monitor patients with cardiogenic shock refractory to conventional medical therapy. Compared to optimal medical care alone, early VA-ECMO, alongside IABP support and effective medical therapy can improve the outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Randomization will be able in centers with extensive experience in AMI and cardiogenic shock, but there is no on-site ECMO team from the nearest ECMO center with sufficient experience in the prevention of AMI and cardiogenic shock, but no on-site ECMO team can establish ECMO before randomization occurs. Physicians at the non-ECMO center will ensure that the ECMO team is immediately available and that an ICU/CCU bed is available at the ECMO center before randomization. If the patient is randomized to the ECMO arm, the mobile ECMO retrieval team will arrive, begin VA-ECMO, and then move the patient on VA-ECMO to the ECMO center in a matter of hours.
Source link: https://clinicaltrials.gov/ct2/show/NCT04184635
According to a significant lactate reduction 24 hours after treatment began, the SCS treatment with the icor kit provides sufficient support for cardiocirculatory function. During diastole, the pump speed and hence the flow are increased, and during systole, the pump rate is set to a relative minimum. Two femoral single vessel cannulas are used in a standard VA ECMO setup. Synchronized Cardiac Support Treatment is used in a Synchronized Cardiac Support Treatment is used in a Synchronized Cardiac Support Treatment.
Source link: https://clinicaltrials.gov/ct2/show/NCT05106491
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions